# To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days

> **NCT02733627** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 36 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** BI 1467335
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02733627
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-07-07
- **Primary completion:** 2017-07-12
- **Final completion:** 2017-07-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2021-06-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02733627

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02733627, "To Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BI 1467335 Following Multiple Dose Administration Over 28 Days". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02733627. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*